Teprotumumab shows promise for thyroid-associated ophthalmopathy


In this multicenter randomized trial, teprotumumab was more effective than placebo in reducing clinical activity and proptosis in patients with active thyroid-associated ophthalmopathy.[Read More …] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/teprotumumab-shows-promise-for-thyroid-associated-ophthalmopathy/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s